 Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022 SAN MATEO, Calif., June 21, 2021 PRNewswire - Sierra Oncology, Inc. NASDAQ: SRRA, a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic. 